Quoin Pharmaceuticals is a brand dedicated to developing therapeutic products for rare diseases. With approximately 300 million people worldwide affected by these diseases, the challenges faced by patients and their families are not uncommon. At Quoin Pharmaceuticals, we are motivated by the courage of patients and their care teams, and we strive to provide solutions for rare diseases.

Our business strategy revolves around putting patients at the center of everything we do. To ensure that our rare disease products reach every patient in need, we have established exclusive international marketing and distribution partnerships covering 60 countries. In addition, we are planning to expand our commercial infrastructure to serve the US and European markets.

Quoin Pharmaceuticals is actively engaged in clinical trials, specifically focusing on evaluating QRX003 as a treatment for Netherton Syndrome. These ongoing studies are conducted under an open U. S.

Investigational New Drug (IND) program. To stay up to date on the latest news and developments from Quoin Pharmaceuticals, you can subscribe to alerts. Join us in our mission to make a difference in the lives of those living with rare diseases